Clinical challenges treating Stenotrophomonas maltophilia infections: An update

Maria F. Mojica; Romney Humphries; John J. Lipuma; Amy J. Mathers; Gauri G. Rao; Samuel A. Shelburne; Derrick E. Fouts; David Van Duin; Robert A. Bonomo

doi:10.1093/jacamr/dlac040

Clinical challenges treating Stenotrophomonas maltophilia infections: An update

Maria F. Mojica, Romney Humphries, John J. Lipuma, Amy J. Mathers, Gauri G. Rao, Samuel A. Shelburne, Derrick E. Fouts, David Van Duin, Robert A. Bonomo

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with in vitro activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of S. maltophilia infections.

Original language	English (US)
Article number	dlac040
Journal	JAC-Antimicrobial Resistance
Volume	4
Issue number	3
DOIs	https://doi.org/10.1093/jacamr/dlac040
State	Published - Jun 1 2022

ASJC Scopus subject areas

Infectious Diseases
Microbiology (medical)
Immunology
Microbiology
Immunology and Allergy

Access to Document

10.1093/jacamr/dlac040

Cite this

@article{60f4306ca14d4a43933a684079613dd3,

title = "Clinical challenges treating Stenotrophomonas maltophilia infections: An update",

abstract = "Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with in vitro activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of S. maltophilia infections.",

author = "Mojica, {Maria F.} and Romney Humphries and Lipuma, {John J.} and Mathers, {Amy J.} and Rao, {Gauri G.} and Shelburne, {Samuel A.} and Fouts, {Derrick E.} and {Van Duin}, David and Bonomo, {Robert A.}",

note = "Publisher Copyright: {\textcopyright} 2022 Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy 2022.",

year = "2022",

month = jun,

day = "1",

doi = "10.1093/jacamr/dlac040",

language = "English (US)",

volume = "4",

journal = "JAC-Antimicrobial Resistance",

issn = "2632-1823",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Clinical challenges treating Stenotrophomonas maltophilia infections

T2 - An update

AU - Mojica, Maria F.

AU - Humphries, Romney

AU - Lipuma, John J.

AU - Mathers, Amy J.

AU - Rao, Gauri G.

AU - Shelburne, Samuel A.

AU - Fouts, Derrick E.

AU - Van Duin, David

AU - Bonomo, Robert A.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with in vitro activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of S. maltophilia infections.

AB - Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with in vitro activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of S. maltophilia infections.

UR - http://www.scopus.com/inward/record.url?scp=85135916716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135916716&partnerID=8YFLogxK

U2 - 10.1093/jacamr/dlac040

DO - 10.1093/jacamr/dlac040

M3 - Review article

C2 - 35529051

AN - SCOPUS:85135916716

SN - 2632-1823

VL - 4

JO - JAC-Antimicrobial Resistance

JF - JAC-Antimicrobial Resistance

IS - 3

M1 - dlac040

ER -

Clinical challenges treating Stenotrophomonas maltophilia infections: An update

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this